Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Pharmaceutical Solutions

All Drugs and Chemicals

In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (\>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

In this group,the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(\>2cm),then drink "Qilisheng"Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Cancer ablation

Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Life information rehabilitation therapy

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable gastric cancer.

By enrolling patients with unresectable gastric cancer adapted to enrolled criteria,this study will document for the first time the synergistic effect of cancer according to local relief degree,progress free survival(PFS)and overall survival(OS).

Bioinformation Therapy for Gastric Cancer

Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresctable Gastric Cancer

It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST）

The duration between treament and cancer recurrence

The duration between treament and patient pass way

Shengxin Biotechnology Institute, Beijing

Fuda Cancer Hospital, Guangzhou

Respiratory Tract (Lung and Bronchial) Diseases

Small Cell Lung Carcinoma

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Small Cell Lung Cancer

In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (\> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

In this group, the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (\> 2 cm), then "Qilisheng" Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable lung cancer.

By enrolling patients with unresectable lung cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Bioinformation Therapy for Lung Cancer

Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Lung Cancer

The duration between treatment and cancer recurrence

The duration between treatment and patient pass away

Gland and Hormone Related Diseases

Pancreatic Neoplasms

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable pancreatic cancer.

By enrolling patients with unresectable pancreatic cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Bioinformation Therapy for Pancreatic Cancer

Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Pancreatic Cancer

Liver Neoplasms

Liver Diseases

Hematinics

Liver Extracts

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable liver cancer.

By enrolling patients with unresectable liver cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Bioinformation Therapy for Gastric Cancer	NCT03350477	Advanced Gastri...	Cancer ablation Life informatio...	20 Years - 80 Years	Fuda Cancer Hospital, Guangzhou
Bioinformation Therapy for Lung Cancer	NCT03239171	Small-cell Lung...	Cancer ablation Life informatio...	20 Years - 80 Years	Fuda Cancer Hospital, Guangzhou
Bioinformation Therapy for Pancreatic Cancer	NCT03239184	Unresectable Pa...	Cancer ablation Life informatio...	30 Years - 70 Years	Fuda Cancer Hospital, Guangzhou
Bioinformation Therapy for Liver Cancer	NCT03239158	Liver, Cancer o...	Cancer ablation Life informatio...	30 Years - 80 Years	Fuda Cancer Hospital, Guangzhou
Bioinformation Therapy for Pancreatic Cancer	NCT03239184	Unresectable Pa...	Cancer ablation Life informatio...	30 Years - 70 Years	Fuda Cancer Hospital, Guangzhou

Spots Global Cancer Trial Database for cancer ablation